spacer
home > > autumn 2017 > qualified matters
PUBLICATIONS


Qualified Matters

Clinical trials are conducted in research settings, designed to answer specific questions about biomedical or behavioural interventions, including new treatments – such as novel vaccines, drugs, dietary choices and supplements and medical devices – as well as known interventions that warrant further study and comparison. They generate critical data on safety and efficacy, which is then submitted to the regulatory authorities responsible for vetting the risk versus benefit ratio of the trial.

As the demand for new therapies and treatments persists, the need for clinical studies expands globally. This comes with a growing need for organisations to ensure they are able to design, start up and execute their trials, thus delivering critical information regarding the results.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Marquard Lett is Senior Advisor at UL Compliance to Performance and has over 38 years’ experience in highly regulated industries, including the pharma industry in manufacturing, training and qualification systems, training quality systems and business and manufacturing process improvement.

Gordon Elger
is Senior Advisor at UL Compliance to Performance and has more than 30 years’ experience in the pharma industry in R&D, manufacturing, regulatory affairs, compliance and document management. He has been responsible for regulatory submissions and liaison with agencies at scientific advice meetings, leading the design and implementation of document management systems and is fully conversant with GxP requirements. Email: gordon.elger@ul.com
spacer
Marquard Lett
spacer
spacer
spacer
Gordon Elger
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

First own Gerresheimer Autoinjector - Gerresheimer and Midas Pharma announce strategic partnership

– Gerresheimer’s first own IP autoinjector suitable for both small and large molecules enhances broad portfolio of solutions, medical devices and pharmaceutical primary packaging – First joint project of Gerresheimer and Midas Pharma: Development and marketing of new autoinjector – One-stop-shop for biotech and pharma customers Duesseldorf, November 08, 2021 – Gerresheimer acquired the IP of a new generation cartridge based autoinjector from Midas Pharma. This is the start of a strategic partnership. The joint project comprises the development and marketing of the new generation autoinjector.
More info >>

White Papers

Clinical Trial-Specific Travel Programs as a Patient Retention Tool

For many patients, participating in a clinical trial is a major endeavor. Depending on the protocol requirements, study visits can be exhausting. There are a number of reasons why a patient may choose to participate in a trial only to drop out. Conversely, there are several approaches to proactively try to prevent this from happening. There are various methods professionals implement for patient retention. This white paper explores patient travel services as one patient retention strategy.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement